These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34189476)

  • 41. Application and optimization of CRISPR-Cas9-mediated genome engineering in axolotl (Ambystoma mexicanum).
    Fei JF; Lou WP; Knapp D; Murawala P; Gerber T; Taniguchi Y; Nowoshilow S; Khattak S; Tanaka EM
    Nat Protoc; 2018 Dec; 13(12):2908-2943. PubMed ID: 30429597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Production of a Chimeric Mouse-Fish Monoclonal Antibody by the CRISPR/Cas9 Technology.
    Ametrano A; Coscia MR
    Methods Mol Biol; 2022; 2498():337-350. PubMed ID: 35727555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of Drug Resistance Mechanisms Using Genome-Wide CRISPR-Cas9 Screens.
    MacLeod G; Rajakulendran N; Angers S
    Methods Mol Biol; 2022; 2535():141-156. PubMed ID: 35867229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene Editing of Mouse Embryonic and Epiblast Stem Cells.
    Sibbritt T; Osteil P; Fan X; Sun J; Salehin N; Knowles H; Shen J; Tam PPL
    Methods Mol Biol; 2019; 1940():77-95. PubMed ID: 30788819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR/Cas9-Based Gene Dropout Screens.
    Wu K; Malek SN
    Methods Mol Biol; 2019; 1881():185-200. PubMed ID: 30350207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR-Cas9 editing of non-coding genomic loci as a means of controlling gene expression in the sea urchin.
    Pieplow A; Dastaw M; Sakuma T; Sakamoto N; Yamamoto T; Yajima M; Oulhen N; Wessel GM
    Dev Biol; 2021 Apr; 472():85-97. PubMed ID: 33482173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation of gene-of-interest double allele knockout clones in primary human T cells by CRISPR.
    Wu L; Tan JC; Gascoigne NRJ
    STAR Protoc; 2023 Sep; 4(3):102445. PubMed ID: 37432856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissecting Tissue-Specific Super-Enhancers by Integrating Genome-Wide Analyses and CRISPR/Cas9 Genome Editing.
    Yoo KH; Hennighausen L; Shin HY
    J Mammary Gland Biol Neoplasia; 2019 Mar; 24(1):47-59. PubMed ID: 30291498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simplified CRISPR-Mediated DNA Editing in Multicellular Eukaryotes.
    Kumar R; Tiwari K; Saudagar P
    Methods Mol Biol; 2023; 2575():241-260. PubMed ID: 36301478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome Editing in Mice Using CRISPR/Cas9 Technology.
    Hall B; Cho A; Limaye A; Cho K; Khillan J; Kulkarni AB
    Curr Protoc Cell Biol; 2018 Dec; 81(1):e57. PubMed ID: 30178917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Robust Protocol for CRISPR-Cas9 Gene Editing in Human Suspension Cell Lines.
    Wardyn JD; Chan ASY; Jeyasekharan AD
    Curr Protoc; 2021 Nov; 1(11):e286. PubMed ID: 34748280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii.
    Shen B; Brown K; Long S; Sibley LD
    Methods Mol Biol; 2017; 1498():79-103. PubMed ID: 27709570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CRISPR-Cas9-Based Genome Editing and Cytidine Base Editing in
    Wang Y; Wang Z; Ji Q
    STAR Protoc; 2020 Jun; 1(1):100025. PubMed ID: 33111078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors.
    Lane-Reticker SK; Kessler EA; Muscato AJ; Kim SY; Doench JG; Yates KB; Manguso RT; Dubrot J
    STAR Protoc; 2023 Mar; 4(1):102082. PubMed ID: 36861834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Multiplexed CRISPR/Cas9 Editing System Based on the Endogenous tRNA Processing.
    Xie K; Yang Y
    Methods Mol Biol; 2019; 1917():63-73. PubMed ID: 30610628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generation of Mouse Model (KI and CKO) via Easi-CRISPR.
    Shola DTN; Yang C; Han C; Norinsky R; Peraza RD
    Methods Mol Biol; 2021; 2224():1-27. PubMed ID: 33606203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanoscale metal-organic frameworks for the intracellular delivery of CRISPR/Cas9 genome editing machinery.
    Zheng Q; Li W; Mao L; Wang M
    Biomater Sci; 2021 Oct; 9(21):7024-7033. PubMed ID: 34378567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.